Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase

NCT ID: NCT00478647

Last Updated: 2021-06-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-07-25
• Study Completion Date: 2009-06-26

Brief Summary

Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this study is to evaluate the safety and efficacy of every other week dosing of GA-GCB (velaglucerase alfa) in participants with type 1 Gaucher disease who were previously treated with imiglucerase.

Detailed Description

Type 1 Gaucher disease, the most common form, accounts for more than 90% of all cases and does not involve the CNS. Typical manifestations of type 1 Gaucher disease include hepatomegaly, splenomegaly, thrombocytopenia, bleeding tendencies, anemia, hypermetabolism, skeletal pathology, growth retardation, pulmonary disease, and decreased quality of life. Gene-Activated® human glucocerebrosidase (GA-GCB; velaglucerase alfa) is produced in a continuous human cell line using proprietary gene-activation technology and has an identical amino acid sequence to the naturally occurring human enzyme. GA-GCB contains terminal mannose residues that target the enzyme to the macrophages-the primary target cells in Gaucher disease. This study was designed to determine the safety of GA-GCB in men, women, and children with Type 1 Gaucher disease who were previously treated with imiglucerase. Each participant's duration of treatment will be 12 months.

Conditions

Gaucher Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

GA-GCB (velaglucerase alfa)

15-60 U/kg, every other week via intravenous infusion

Group Type: EXPERIMENTAL

GA-GCB (velaglucerase alfa)

Intervention Type: BIOLOGICAL

15-60 U/kg, every other week via intravenous infusion

Interventions

GA-GCB (velaglucerase alfa)

15-60 U/kg, every other week via intravenous infusion

Intervention Type: BIOLOGICAL

Other Intervention Names

gene-activated® human glucocerebrosidase; VPRIV®; GA-GCB

Eligibility Criteria

Inclusion Criteria

Includes:

• The participant has a documented diagnosis of type 1 Gaucher disease, as determined by deficient glucocerebrosidase (GCB) activity relative to normal as measured in leukocytes or by genotype analysis and the participant/legal guardian is willing and able to provide written informed consent prior to initiating any study-related procedures
• The participant has received consistent treatment with imiglucerase at a dose ≤ 60 U/kg and ≥ 15 U/kg every other week for a minimum of 30 consecutive months. Participants who are anti-imiglucerase antibody positive will be allowed to enter this study
• The participant is at least 2 years of age
• Female participants of child-bearing potential agree to use a medically acceptable method of contraception. Male participants must agree to use a medically acceptable method of birth control
• Participant must be sufficiently co-operative to participate in the study as judged by the Investigator.

Exclusion Criteria

Includes:

• The participant has type 2 or 3 Gaucher disease or is suspected of having type 3 Gaucher disease
• The participant has received treatment with any investigational drug or device within the 30 days prior to study entry; such use during the study is not permitted
• Participant is HIV positive
• Participant is hepatitis B/C positive
• The participant presents with sustained iron, folic acid and/or vitamin B12 deficiency-related anemia during Screening
• The participant, participant's parent(s), or participant's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study
• The participant has a significant comorbidity that might affect study data or confound the study results
• The participant is unable to comply with the protocol or is otherwise unlikely to complete the study, as determined by the Investigator
• The participant has experienced an anaphylactic/anaphylactoid reaction during treatment with imiglucerase
• The participant has received miglustat during the 6 months prior to study enrollment
• The participant has an active, clinically significant spleen infarction
• The participant has active, progressive bone necrosis
• The participant is a pregnant and/or lactating female

• Minimum Eligible Age: 2 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shire

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Study Director

Role: STUDY_DIRECTOR

Takeda

Locations

Regional Metabolic Center

Los Angeles, California, United States

Children's Hospital Oakland

Oakland, California, United States

Emory University

Decatur, Georgia, United States

Feinberg School of Medicine

Chicago, Illinois, United States

Children's of Minnesota

Minneapolis, Minnesota, United States

Children's Mercy Hospital and Clinic

Kansas City, Missouri, United States

NYU School of Medicine

New York, New York, United States

Cincinatti Children's Hospital

Cincinnati, Ohio, United States

Texas Children's Hospital

Houston, Texas, United States

Medical Genetics/Pediatrics

Salt Lake City, Utah, United States

Children's Hospital of Wisconsin

Milwaukee, Wisconsin, United States

Shaare Zedek Medical Center

Jerusalem, , Israel

Children's Memorial Health Institute

Warsaw, , Poland

Hospital Universitario Miguel Servet

Zaragoza, , Spain

The Royal Free Hospital

London, , United Kingdom

Countries

United States; Israel; Poland; Spain; United Kingdom

References

Zimran A, Pastores GM, Tylki-Szymanska A, Hughes DA, Elstein D, Mardach R, Eng C, Smith L, Heisel-Kurth M, Charrow J, Harmatz P, Fernhoff P, Rhead W, Longo N, Giraldo P, Ruiz JA, Zahrieh D, Crombez E, Grabowski GA. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. Am J Hematol. 2013 Mar;88(3):172-8. doi: 10.1002/ajh.23383. Epub 2013 Jan 22.

Reference Type: RESULT

PMID: 23339116 (View on PubMed)

Other Identifiers

2006-006304-11

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

TKT034

Identifier Type: -

Identifier Source: org_study_id